Having rolled off the production line, the first batch of a COVID-19 vaccine produced by a Shanghai pharmaceutical company will soon be on the market, thus filling the gap in Shanghai's COVID-19 vaccine production.

Convidecia is a recombinant novel coronavirus vaccine (Adenovirus Type 5 Vector) co-developed by CanSinoBIO and the Academy of Military Medical Sciences and received conditional approval by the National Medical Products Administration on Feb 25, 2021. One shot of the vaccine provides rapid protection for 14 days, so as to achieve herd immunity at a faster pace and reduce vaccination costs and workload.

It is also reported that CanSinoBIO will also begin work on producing an inhalable COVID-19 vaccine by working with medical scientist Chen Wei’s team.